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The metabolic profiling of human amniotic fluid (HAF) is
of potential interest for the diagnosis of disorders in the
mother or the fetus. In order to build a comprehensive
metabolite database for HAF, hyphenated NMR has been
used, for the first time, for systematic HAF profiling.
Experiments were carried out using reverse-phase (RP)
and ion-exchange liquid chromatography (LC), in order
to detect less and more polar compounds, respectively.
RP-LC conditions achieved good separation of amino
acids, some sugars, and xanthines. Subsequent NMR and
MS analysis enabled the rapid identification of 30 com-
pounds, including 3-methyl-2-oxovalerate and 4-amino-
hippurate identified in HAF for the first time, to our
knowledge. Under ion-exchange LC conditions, a different
set of 30 compounds was detected, including sugars,
organic acids, several derivatives of organic acids, and
amino acids. In this experiment, five compounds were
identified for the first time in HAF: D-xylitol, amino acid
derivatives (N-acetylalanine, N-acetylglycine, 2-oxoleu-
cine), and isovalerate. The nonendogenous nature of some
metabolites (caffeine, paraxanthine, D-xylitol, sorbitol) is
discussed. Hyphenated NMR has allowed the rapid detec-
tion of ∼60 metabolites in HAF, some of which are not
detectable by standard NMR due to low abundance (µM)
and signal overlap thus enabling an extended metabolite
database to be built for HAF.
Proton NMR spectroscopy has become a routine tool for fast,
comprehensive characterization of complex mixtures,1 including
biofluids,2–5 liquid foods,6–8 and plant extracts.9–13 Such detailed
characterization is particularly useful in metabonomic studies that
aim to understand the effects of perturbations on living systems
through the measurement of changes in their metabolome. 1H
NMR spectroscopy enables the identification of many tens or
hundreds of compounds simultaneously, is noninvasive, and
requires little or no sample preparation. The use of autosampling
methods for large numbers of samples to enable statistical
validation of the data is also common place. However, when
complex mixtures are analyzed, preferably without any previous
sample simplification like extraction or separation, the issue of
spectral complexity is a serious hindrance due to extensive signal
overlap. The desired level of compound identification depends on
the problem addressed, and often, partial assignment of the
spectra for a selection of compounds (or family of compounds)
will suffice. Also, in classification studies where reproducible
sample differences are detected and validated by a range of
increasingly sophisticated chemometrics methods, the full as-
signment of these changes may not always be necessary. In the
case of biological fluids and tissues, the quest is often to find
specific compounds that may be used as markers for some kind
of system perturbation, e.g., disease, diet, and medication. Often,
the nature of these markers is not known in advance, and hence,
further unveiling of spectral overlap may be of crucial importance.
The development of hyphenated NMRmethods, with the coupling
of an HPLC step immediately prior to NMR analysis (LC-NMR)
enables compound separation and analysis to be carried out
* To whom correspondence should be addressed. Tel.: +351 234 370707. Fax:
+351 234 370084. E-mail: agil@ua.pt.
† CICECO-Department of Chemistry, University of Aveiro.
‡ University of Coimbra.
§ Centro Hospitalar de Coimbra.
| Mass Spectrometry Centre, Department of Chemistry, University of
Aveiro.
⊥ Bruker Biospin GmbH.
(1) Fan, T. W. M. Prog. Nucl. Magn. Reson. Spectrosc. 1996, 28, 161–219.
(2) Sean, X. P. Biomed. Chromatogr. 2000, 14, 430–441.
(3) Corcoran, O.; Spraul, M. Drug Discovery Today 2003, 8, 624–631.
(4) Dear, G. J.; Plumb, R. S.; Sweatman, B. C.; Parry, P. S.; Roberts, A. D.;
Lindon, J. C.; Nicholson, J. K.; Ismail, I. M. J. Chromatogr., B: Biomed. Sci.
Appl. 2000, 748, 295–309.
(5) Lindon, J. C.; Nicholson, J. K.; Wilson, I. D. J. Chromatogr., B: Biomed. Sci.
Appl. 2000, 748, 233–258.
(6) Gil, A. M.; Duarte, I. F.; Godejohann, M.; Braumann, U.; Maraschin, M.;
Spraul, M. Anal. Chim. Acta 2003, 488, 35–51.
(7) Le Gall, G.; Colquhoun, I. J.; Davis, A. L.; Collins, G. J.; Verhoeyen, M. E.
J. Agric. Food Chem. 2003, 51, 2447–2456.
(8) Anatoli, P.; Sobolev, A. S. R. L. Magn. Reson. Chem. 2003, 41, 237–245.
(9) Jean-Luc, Wolfender.; Emerson F., Queiroz.; Hostettmann, K. Magn. Reson.
Chem. 2005, 43, 697–709.
(10) Vassiliki, Exarchou.; Manfred, Krucker.; Teris, A.; van, Beek.; Jacques,
Vervoort.; Ioannis P., Gerothanassis.; Albert, K.Magn. Reson. Chem. 2005,
43, 681–687.
(11) Jean-Luc, Wolfender.; Hostettmann, K. N. K. Phytochem. Anal. 2001, 12,
2–22.
(12) Jaroszewski, J. Planta Med. 2005, 691, 700.
(13) Jaroszewski, J. Planta Med. 2005, 795, 802.
Anal. Chem. 2008, 80, 6085–6092
10.1021/ac800907f CCC: $40.75  2008 American Chemical Society 6085Analytical Chemistry, Vol. 80, No. 15, August 1, 2008































































quickly.14 Further advances, driven mostly by the need to improve
sensitivity, include cryoprobe technology,15 coupling with mass
spectrometry (MS) (LC-NMR/MS),3,16 solid-phase extraction
(SPE) of hydrophobic compounds,16 and several LC developments
such as ultraperformance liquid chromatography.17 In addition,
increasingly sophisticated data analysis methodologies are emerg-
ing to aid and speed up the analysis and interpretation of
hyphenated NMR data.18,19
Hyphenated NMR methods have shown promise in fields such
as toxicology, drug metabolism, and biomarker identification.5,20
Some examples include the detection of metabolites of ibuprofen
and acetaminophen in urine,15,21 identification of biomarkers for
kidney xenobiotic toxicity,22 and characterization of lipoproteins
in human blood serum.23 The majority of hyphenated NMR
studies on natural or biological mixtures have involved the use
of reverse-phase (RP) LC columns, and this approach may be of
limited use if the composition in terms of more polar metabolites
is to be assessed. In these cases, ion-exchange or hydrophilic
interaction chromatography4,24 LC columns need to be employed.
In this work, the extent to which hyphenated NMR can add
to the compositional information on human amniotic fluid
(HAF), compared to 1D and 2D NMR spectroscopy, is evaluated
for both polar and nonpolar compounds. The choice of this
biological fluid is justified by its potential for the understanding
and diagnosis of several perturbations of the health of fetuses
and their mothers. Early attempts to correlate 1H NMR spectra
of HAF with the occurrence of disorders such as spina bifida
and chromosome-derived disorders in the fetus and pre-
eclampsia or gestational diabetes in the mother have been
carried out;25 however, extended spectral assignment and
statistical validation are required. A recent 1D and 2D NMR
study has enabled the identification of up to 50 metabolites in
HAF;26 however, many minor compounds were detected for
which no assignment could be achieved. The use of hyphenated
NMR methods in tandem with cryotechnology is shown here
to aid the identification of some of these metabolites in HAF
and the usefulness of both reverse-phase and ionic-exchange
LC experiments is compared and discussed. A more complete
database of metabolites has thus been built for HAF, against
which compositional changes may be detected and measured
in metabolic studies of fetuses and mother disorders.
EXPERIMENTAL SECTION
Samples. Amniotic fluid samples were obtained from healthy
pregnant women with ages of>35 and at a gestation time of 16-17
weeks, under ethical committee approval (Comissa˜o E´tica para a
Sau´de, Maternidade Bissaya Barreto, Centro Hospitalar de Coim-
bra). The samples of HAF (15-20 mL) were centrifuged (177.4g,
22 °C, 10 min) and the supernatants collected and frozen at -70
°C for up to 4 months, until NMR analysis. All samples were
ultrafiltered through 3 kDa cutoff Nanosep 3K Omega centrifuge
membrane filters (Pall Corp.). The resultingMw < 3 kDa fractions
were freeze-dried, reconstituted in D2O to 10 times the initial
concentration, centrifuged, and the supernatants used for analysis.
1D 1H NMR of whole HAF. The 1D 1H NMR spectrum of
an HAF sample, prepared as described above, was recorded on a
Bruker Avance spectrometer with a cryo-probe, operating at 600.13
MHz for 1H. A “noesypr1d” pulse sequence (RD-90°-t1-90°-
tm-90°-acquire) was used, with a 13.20 µs 90° pulse, 100 ms
mixing time (tm), 4 µs t1, and 4 s relaxation delay and 32 transients
were collected into 32K data points for a 8865.25 Hz spectral width.
Water presaturation was performed at 2816.62 Hz during the
relaxation delay and mixing time. After exponential multiplication
of the free induction decay (FID) with a 0.3 Hz line-broadening
function, Fourier transformation was performed and the spectrum
manually phased, automatically baseline corrected, and chemical
shifts referenced internally to the anomeric proton of R-D-glucose
at 5.23 ppm.
Hyphenated NMR Methods. Instrumentation. The HPLC
equipment consisted of either an Agilent 1100 or Agilent 1200
solvent delivery system with a quaternary pump, solvent degasser,
autosampler, DAD (Agilent, Waldbronn), and column oven. The
Agilent 1100 system was connected through a BPSU-36/2 interface
(Bruker BioSpin, Rheinstetten, Germany) to an NMR Avance
spectrometer, working at 500.17 MHz for proton, with a 3 mm
LCSEI probe head (60 µL active volume) and an Esquire 3000
electrospray ion trap mass spectrometer (Bruker Daltonics,
Bremen, Germany); the Agilent 1200 system was connected to
an Avance 600 MHz spectrometer with cryoprobe (Bruker
BioSpin). To confirm some of the results (repetition of 1D and
2D NMR on selected LC fractions), an Agilent 1100 system
connected to a DRX-500 NMR spectrometer was used, with a
1H-13C inverse detection flow probe.
LC-NMR/MS and LC-SPE-NMR for Detection of Less-Polar
Compounds. For detecting less-polar compounds, samples were
injected onto a Phenomenex RP C18 column at 35 °C, using a
mobile phase (pH 2.0) consisting of a mixture of solution A (D2O
+ 0.1% formic acid deuterated to 90%) and solution B (acetonitrile
+ 0.1% formic acid deuterated to 90%), with the following gradient
program: 10-30% B from 0 to 40 min and then from 30 to 90% B
from 40 to 45 min. Sample volumes were 100 µL, and DAD
detection was set at 200-210 and 254-280 nm. 1H NMR spectra
were recorded at 500.17 MHz using the loop-sampling method.
The “lc1pncwps” pulse sequence from Bruker library with double
solvent presaturation was employed, with 512, 1024, or 2048
transients (depending on the chromatographic peak intensity),
16k data points, a spectral width of 10 000 Hz, and 0.8 s acquisition
time. Each FID was zero-filled to 32k, multiplied by an exponential
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function (1 Hz line broadening), manually phased, and baseline
corrected. For selected fractions, 1H-1H TOCSY spectra were
recorded. MS and MSn data were acquired during the chromato-
graphic run in positive mode and during fraction transfer in both
positive and negative modes, using the mass range 50-1000m/z. A
spray voltage of 3500 V was applied; N2 was used as sheath gas at
60 psi, 11 L/min and at 350 °C as dry gas. For LC-SPE-NMR, the
injection volume was 20 µL and all other chromatographic conditions
were the same. Selected peaks were trapped into SPE cartridges and
extracted with either methanol-d4 or acetonitrile before transfer
through a Prospekt interface into the cryoprobe head with cryofit
(30 µL active volume). 1HNMR spectra were recorded at 600.13MHz
using the parameters described above.
LC-NMR and LC-MS for Detection of More-Polar Compounds.
For detection of polar compounds, samples were injected onto a
ION300 300 × 7.8 mm cation-exchange column, with a particle
size of 5.0 µm (Interaction Chromatography Inc., San Francisco,
CA) specific for organic acids, alcohols, and sugars, at a temper-
ature of 22 °C, under isocratic conditions. For LC-NMR, 100 µL
injection volumes and a mobile phase composed of 2.5 mM H2SO4
in 100% D2O (pH 2.4) were used, whereas for LC-MS, the volume
injected was 20 µL and D2O was replaced by water in the mobile
phase. 1H NMR spectra were recorded at 600.13 MHz (with a
cryoprobe and a 120 µL active volume) using the time-sliced stop-
flow method. The “lc1pnf2” sequence from the Bruker pulse
program library was used, with water presaturation at 2817.22 Hz,
a flow of 0.3 mL/min, and a total run time of 70 min. Every 30 s,
the flow was stopped and a 1D spectrum collected with 64
transients, 32k data points, spectral width of 12019 Hz, and 1.36 s
acquisition time. Each FID was multiplied by an exponential
function (1 Hz line broadening), manually phased, and baseline
corrected. Mass spectra were collected in both positive and
negative modes, in the mass range of 90-1000 m/z, with auto
MSn.
RESULTS AND DISCUSSION
Identification of Less-Polar Compounds in HAF by Re-
verse-Phase LC Hyphenated to NMR and MS. The LC and
MS chromatograms obtained for HAF fractions with Mw < 3 kDa,
run on a RP-C18 column with DAD detection at 200-210 nm
(Figure S1a, Supporting Information), result from the early elution
(in the first 10 min) of the majority of HAF metabolites, of a polar
nature, followed by elution of the more hydrophobic compounds.
Several fractions were collected in loops (the numbering shown
in Figure S1a relates to loop number) and stored for NMR
analysis. Figure 1b-f shows the 1H NMR spectra of some of these
LC fractions, compared to the spectrum of the whole HAF sample
(Figure 1a). The spectrum of loop 1, at 6.51-min retention time
(RT) shows overlapping profiles of several coeluting polar
molecules such as amino acids (alanine, lysine, glutamine and
glutamate, threonine), organic acids (citrate and lactate), sugars
and polyalcohols (glucose, myo-inositol), and others (betaine,
creatine, choline). Spin systems from compounds eluting at later
retention times (Figure 1c-f) present much cleaner spectral
profiles, enabling detailed assignment to be carried out.
Figure 1. 1H NMR spectra of (a) whole HAF fraction with Mw < 3 kDa and selected fractions resulting from its analysis by RP-C18 LC-NMR/
MS: (b) loop 1, several coeluting compounds at RT < 10 min; (c) loop 8, containing tryptophan; (d) loop 9, containing 4-aminohippurate; (e) loop
11, containing caffeine; (f) loop 14, containing 3-methyl-2-oxovalerate. Loop numbers correspond to those shown in Figure S1. Un., unassigned
peak; RG, receiver gain; NS, number of transients.































































Table 1lists all the assigned spin systems and MS information
resulting from the reverse-phase LC-NMR/MS (the superscript “b”
identifies compounds newly detected by NMR in HAF), as well as
the main unassigned spin systems. Some contaminant compounds
found to be present in the LC-NMR system or in themembrane filters
used to prepare theMw < 3 kDa HAF fraction are also listed. A total
of 30 compounds were assigned in this experiment, using previous
work,26 a compound database search (mainly in Brukers BioSpin
BBiorefcode 2.0.0 standard compound database), and, whenever
possible, the recording of spectra of standard compounds at the pH
of the experiment (pH 2). 4-Aminohippurate and 3-methyl-2-oxoval-
erate (Figure 1d,f) have been identified for the first time, to our
knowledge, in HAF. Mannose, caffeine, paraxanthine, tryptophan,
and hippurate, previously detected in HAF by several other analytical
methods,27–30 have been identified here for the first time by NMR,
in one single experiment.
Caffeine and paraxanthine (1,3,7-trimethylxanthine and 1,7-
dimethylxanthine, respectively) are not usually endogenous in
Table 1. Results of LC-NMR/MS on HAF Using a RP-C18 Column (at pH 2.0)a
MS (m/z)
loop no. RT (min) MS MS/MS δ1H, ppm (multiplicity, J in Hz, assignment) compound
expected
concentration (µM)
1/6.51 1.49(d, 7.3, CH3) alanine 32328
193.8f 2.77(AB, 15.3, CH2), 2.86(AB, 15.0, CH2) citrate 34535
202.8f 3.41(t, H4), 3.52(dd, H2), 3.70(t, H3), 3.76(dd, H6),
3.83(m, H5), 5.23(d, H1)
R-D-glucose 251035
202.8f 3.24(dd, H2), 3.40(t, H4), 3.49(t, H3), 3.47(dd, H5),
3.73(dd, H’6), 3.90(dd, H6), 4.64(t, H1)
-D-glucose
153.1 1.49(m, γCH2), 1.73(m, δCH2), 1.91(m, CH2),
3.03(t, 7.5, CH2)
lysine 20228
153.0 2.13(m, CH2), 2.50(m, γCH2) glutamine, glutamate 18635, 22735
202.8f 3.28(t, H5), 3.62(t, H4/H6), 4.06(t, 2.9, H2) myo-inositol 39636
1.33(d, 6.6, γCH3), 4.27(ABX, CH2) threonine 15628
2/7.12 3.27(s, CH3) betaine 6636
3.05(s, CH3) creatine 99.836
3.20(s, CH3), 4.06(m, CH2) choline 1128
90.0f 1.38(d, CH3), 4.26(q, CH) lactate 980035
160.9 7.41(s, ring H4), 8.48(s, ring H2) histidine 9728
2.00(m, γCH), 2.35(m, γCH′), 4.13(m, RCH) proline 18128
3.56(s, CH3) glycine 16728
4.89(d, H’6), 5.18(d, H6) D-mannoseb
1.00(d, 7.0, CH3), 1.05(d, 7.0, CH3), 2.29(m, CH) valine 15328
4/9.50 3.14(s, CH3) creatinine 4428
153.9 133.9 2.14(s, SCH3), 2.24(m, CH2), 2.67(t, γCH2),
4.01(dd, RCH2)
methionine 1428
5/10.01 135.9 88.3 0.98(t, 6.2, δCH3), 1.74(m, γCH), 1.81(m, CH2),
3.91(m, RCH)
leucine 6828
135.9 88.3 0.96(t, 7.4, δCH3), 1.04(d, 7.0, CH3), 1.32(m,
γCH), 1.51(m, γCH), 3.86(d, 3.7, RCH)
isoleucine 2928
186.8 166.8 3.11(ABX, CH), 3.25(ABX, CH′), 4.10(dd, RCH),
6.91(d, 8.5, ring H3), 7.21(d, 8.5, ring H2)
tyrosine 5135
6/12.11 169.8 66.8f 122.0 3.16(ABX, CH), 3.32(ABX, CH′), 4.12(dd, RCH),
7.34(m, ring H6), 7.39(m, ring H4), 7.44(m, ring
H3/H5)
phenylalanine 5328
7/14.27 183.0 3.50(s, CH3), 3.95(s, CH3), 7.93(s, CH) paraxanthineb
8/17.26 209.9 202.8f 190.8 3.38(ABX, CH), 3.52(ABX, CH′), 4.21(ABX,
RCH), 7.21(t, ring H5/H6), 7.29(t, ring H5/H6),
7.33(s, ring H2), 7.55(d, ring H7), 7.72(d, ring
H4)
tryptophanb 1028
9/17.79 3.91(s, CH2), 6.98(d, ring H3/H5), 7.98(d, ring
H2/H6)
4-amino-hippuratec
11/24.19 196.0 194.9e 138.8 3.37(s, CH3), 3.56(s, CH3), 3.98(s, CH3), 7.92(s,
ring H2)
caffeineb
13/29.54 4.19(s, CH2), 7.58(t, H3/H5), 7.86(d, H2/H6) hippurateb
14/35.50 0.91(t, 7.4, CH3), 1.11(d, 7.0, CH3), 1.45(m, CH),
1.72(m, CH′), 3.00(m, CH)
3-methyl-2-oxovalerateb
loop no./RT (min) unassigned spin systems δ1H, ppm (multiplicity) signals from contaminants δ1H, ppm (multiplicity)
2/7.12 3.30(s); 3.23(s); 3.60(s); 4.48(s); 7.37(s), 7.43(s) 3.56(dd), 3.65(dd), 3.77(m) glycerol (membrane filter)
3/7.93 1.15(d); 1.25(d); 1.10(m) 3.35(s) methanol (system)
4/9.50 1.14(d), 3.45(m), 3.53(dd); 3.88(d) 0.93(t); 0.95(s); 1.14(s); unidentified (system)
5/10.01 1.14(d); 1.18(t); 3.14(s); 3.65(s) 1.18(d); 1.43(d); 1.26(t) unidentified (system)
9/17.79 3.33(s); 3.91(s); 3.97(s)
12/29.09 3.19(s); 3.66(s); 4.19(s); 7.37(t), 7.58(m)
a Loop numbers are those used in Figure S1. Expected concentration values (for 2nd trimester of pregnancy) are shown in the last column.
b Newly found by NMR. c Tentative assignment, no MS information available. MS and MS/MS m/z values correspond to [M + D]+ adducts except
those in footnotes d-f. d Values correspond to [M - D]. e Values correspond to [M + H]+. f Values correspond to [M + Na]+.































































humans and paraxanthine is the main metabolite of caffeine. The
presence of these compounds in HAF most probably arises from
maternal ingestion of caffeine-containing beverages, e.g., coffee,
and consequent fetal excretion into the amniotic fluid. This was
indeed confirmed by consultation of the medical records of the
donors. The detection and quantitation of these metabolites in
HAF is of considerable interest due to their possible adverse
effects on mother’s and fetus’ health. These compounds have been
first detected in HAF by gas chromatography and mass spec-
trometry,29 and a more recent capillary electrophoresis study30
had reported the presence of a xanthine compound in HAF
although no comment was made as to its origin. LC-NMRmethods
may, in principle, be employed to quantify these metabolites, as
long as an adequate reference compound and finely controlled
experimental conditions are used throughout the duration of the
experiment, in order to ensure fixed and constant flux values. This
is, however, beyond the scope of the present work.
Tryptophan is a known component of HAF, although its
detection by 1H NMR had not been reported before, most probably
due to its low concentration. Indeed, expected concentrations lie
in the 4.7-18.0 µM range, as determined by capillary electro-
phoresis for the same maternal age and gestation times considered
here.28 Unlike hippurate, which is ubiquitous in human urine15
and has been detected in HAF before,31 endogenous 4-aminohip-
purate has not, to our knowledge, been observed in HAF. This
compound is sometimes employed for measurement of amniotic
fluid volume;32 however, this procedure was not carried out here
and it may be concluded that the compound detected is of an
endogenous origin.
LC-SPE-cryo-NMR was attempted for the peaks eluting after
10 min RT (Supporting Information, Figure S1), in order to
characterize other nonpolar metabolites. However, the corre-
sponding 1H NMR spectra (data not shown) did not add any
further metabolite information, due to the poor compound reten-
tion in the SPE cartridges employed.
Identification of More-Polar Compounds in HAF by Ion-
Exchange LC Hyphenated to NMR. The LC and MS chromato-
grams obtained for the analysis of a Mw < 3 kDa HAF fraction on
a cation-exchange column are shown in Figure S1b (Supporting
Information). The intensity of the MS signal was relatively low,
compared to that obtained for the RP experiment, reflecting poor
ionization of the polar compounds separated by the cation-
exchange column used here.
(27) Ng, K. J.; Andresen, B. D.; Bianchine, J. R.; Iams, J. D.; O’Shaugnessy,
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Pharmacol. 1975, 12 (3), 583–95.
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Figure 2. (a) LC-NMR 2D chromatogram recorded with an ION300 LC-NMR experiment of a 10-fold concentrated HAF fraction with Mw < 3
kDa (the apparent distortion at earlier RTs is due to empty volume effects) and (b) selected lines taken from (a), for retention times of 20
(containing 3-methyl-2-oxovalerate), 23 (containing malate), 25.7 (containing D-xylitol), and 32 min (containing hydroxypropionate). RG, 724;
NS: 64 for all lines; Un, unassigned peak.































































Figure 2a shows the corresponding pseudo-two-dimensional
LC-NMR chromatogram where each row is the 1D 1H NMR
spectrum corresponding to each RT of the chromatographic
experiment. The large spread of signals in this plot shows that
separation of a large number of compounds was achieved. This
follows preliminary results obtained for HAF, at lower field
strength (500 MHz) using a noncryoprobe, which led to the
identification, for the first time, of malic acid in HAF.26 Indeed,
the improved resolution and sensitivity of the experimental
conditions used here have enabled the detection of a greater
Table 2. Results of LC-NMR on HAF Using an Ion-Exchange ION300 Column (at pH 2.4)a
MS (m/z)
RT (min) MS MS/MS δ1H, ppm (multiplicity, J in Hz, assignment) compound
expected
concentration (µM)
14.0 3.2 (s), 3.3 (s), 3.6-4.0 (broad profile) methoxylated oligosaccharide (U2)a
16.0 407.0 214.5 3.6-3.9, 4.35, 4.99 (d), 7.40 (s) pentose
19.0 0.94(d, 7.0, γCH3) isovaleratea,b
19.5 2.85(AB, CH2, 15.8), 3.03(AB, 15.8, CH2) citrate 34535
2.38(s, CH3) pyruvate
1.58(s, CH3) pyruvate (hydrate form)
20.0 0.89(t, 7.5, δCH3), 1.09(d, 6.8, ’CH3), 1.46(m,
γCH), 1.68(m, γ’CH), 2.92(m, CH)
3-methyl-2-oxovalerateb
20.5 202.8 3.41(t, H4), 3.52(dd, H2), 3.70(t, H3), 3.76(dd, H6),
3.83(m, H5), 5.23(d, H1)
R-D-glucose 251035
202.8 3.24(dd, H2), 3.40(t, H4), 3.49(t, H3), 3.47(dd, H5),
3.73(dd, H’6), 3.90(dd, H6), 4.64(t, H1)
-D-glucose
324.9 162.8d 3.12(dd), 3.29(m), 3.36(m), 3.59(m), 3.66(m),
3.96(dd), 4.01(dd), 4.12(m), 4.25(d), 4.32(t),
4.50(d), 5.50(d)
hexose disaccharideb
21.0 0.94(d, 6.8, γCH3), 2.09(m, CH) 2.64(d, RCH) 2-oxoleucineb
21.5 202.8 3.26(t, H5), 3.61(dd, H4/H6), 4.05(t, H2) myo-inositol 39636
22.0 202.8 3.56(t, H3), 3.64(m, H3/H4), 3.93(m, H2), 4.90(d,
H’6), 5.18(d, H6)
D-mannoseb
22.5 202.8 3.57(m, H1), 3.80(d, H6), 3.99(m, H4), 4.03(dd,
H5), 4.11(d, H3)
D-fructoseb
23.5 2.85(ABX, CH), 2.92(ABX, CH′), 4.57(dd, RCH) malate
24.5 182.8d 164.8d 65.9d 3.63(m, H1/H4/H6), 3.73(d, H6), 3.76(m, H3),
3.82(d, H1), 3.84(m, H2/H5)
sorbitolb
25.7 3.65(m, H3), 3.72(dd, H1/H5), 3.80(m, H2/H4) D-xylitolb
30.5 1.42(d, 7.1, CH3), 4.38(q, 7.0, CH) lactate 980035
30.8 3.26(t, 6.6, CH2), 3.43(t, 6.6, CH2) taurine 8335
31.5 2.62(t, 6.0, CH2), 3.86(t, 5.9, CH2) hydroxypropionateb 9.5-2733
32.0 2.68(s, CH2) succinate
8.45(s, CH) formate
32.5 1.25(d, 6.4, γCH3), 2.51(ABX, CH), 2.59(ABX,
CH′), 4.24(m, RCH)
3-hydroxybutyrate 12035
33.5 1.34(s, CH2), 2.57(s, CH2) 2-hydroxyisobutyrate
33.7 0.96(t, 7.5, γCH3), 1.74(m, CH), 1.84(m, CH′),
4.25(m, RCH)
2-hydroxybutyrate 5035
35.0 2.32(s, CH3) acetoacetic
35.5 2.09(s, CH3) acetate
37.2 6.81(s, CH) fumarate
38.5 0.90(d, 6.9, γCH3), 1.00(d, 6.9, γ’CH3), 2.06(m,
CH), 4.12(d, 4.3, RCH)
2-hydroxyisovalerate
44.0 2.06(s, NCH3), 3.96(s, RCH2) N-acetylglycineb
45.0 2.17(m, γCH), 2.43(m, CH2), 2.56(m, γCH′),
4.37(dd, RCH)
pyroglutamatea, b 19-5033
46.0 3.23(s, CH3) acetylcholineb
46.5 1.41(d, 7.3, CH3), 2.03(s, NCH3) N-acetylalanineb
53.5 2.69(t, 7.0, CH2), 3.45(t, 7.1, CH2) 2-oxoglutaratec
unassigned spin systems
RT (min) δ1H, ppm (multiplicity) RT (min) δ1H, ppm (multiplicity) RT (min) δ1H, ppm (multiplicity)
12.5 1.0 (m), 1.6 (d), 3.9 (s) (U1) 25.5 3.62(m), 3.68(m), 3.78(dd) 35.8 3.44(dd), 3.54(dd)
15.0 3.91(s) 3.56(dd), 4.35(d) 40.5 0.93(d), 3.74(t)
16.0 3.20(s), 3.33(s) 25.8 1.26(d), 1.32(d) 40.8 2.46(s)
3.77(m), 3.97(d), 4.99(m), 7.46(s) (U3) 26.5 1.27(d), 1.43(s) 42.5 1.18(t)
16.5 2.50(d), 2.75(m) 28.8 3.86(t), 4.54(s), 4.58(s) 43.0 3.15(s)
18.0 0.95(d) 29.5 3.60(s) 43.5 1.10(t)
1.13(d) 30.0 4.21(s) 48.0 1.22(s)
20.3 2.73(dd), 2.88(dd) 35.5 1.14(d, 7.1), 2.72(m), 3.72(d, 6.2) 49.0 1.15(d)
23.5 3.65(m) 3.67(s) 50.5 2.80(s)
24.5 1.19(d) 36.0 2.20(s) 63.0 1.20(d)
64.0 0.96(d)
a Expected concentration values (for 2nd trimester pregnancy) are shown in the last column. b Newly found by NMR. c Tentative assignment.
MS and MS/MS m/z values correspond to [M + Na]+ adducts. d Values corresponding to [M + H]+.































































number of compounds in HAF. Table 2 shows that just over 30
compounds have been identified, mainly comprising sugars and
organic acids, together with several derivatives of both organic
acids and amino acids (again, the superscript “b” identifies
compounds newly detected by NMR in HAF). Some of the
compounds assigned (pyroglutamate, hydroxypropionate, D-man-
nose, D-fructose, sorbitol) had been previously found in HAF in
several studies,28,33,34 and a further five compounds were identified
in HAF here for the first time, to our knowledge. These comprise
D-xylitol, the amino acid derivatives N-acetylalanine, N-acetylgly-
cine, and 2-oxoleucine, and isovalerate. The spectra of selected
fractions (Figure 2b) show the relatively low signal intensity of
some of the compounds identified.
In addition, previous tentative assignments based on NMR
alone26 were confirmed by the results obtained here, namely, for
myo-inositol, 3-hydroxybutyrate and 2-hydroxybutyrate, and 2-hy-
droxyisovalerate, for which either low-intensity or incomplete spin
systems are observed by 1D and 2D NMR. In the lower section
of Table 2, a list of unidentified spin systems is shown, based on
the concomitant intensity changes seen for consecutive rows (or
spectra) in the plot shown in Figure 2a. Many of these are singlets
and, therefore, difficult to identify by LC-NMR alone. In fact, LC-
MS analysis was also carried out, although in an off-line mode
due to limitations in the experimental conditions available.
However, as mentioned before, the poor compound ionization in
both positive and negative modes prevented significant MS
information to be added to the LC-NMR results.
Regarding sugars or sugar-like compounds, the newly found
D-xylitol and sorbitol are, like caffeine and paraxanthine, exog-
enous metabolites possibly originating from the use of sweeteners
or inclusion of some stone fruits (plums, berries) in the maternal
diet. It is also noted that a hexose disaccharide (as shown by MS)
coelutes with glucose at 20.5-min retention time (Table 2);
however, further assignment was not possible at this stage. In
addition, an interesting group of weaker signals resonating in the
sugar region may be seen at earlier retention times (between 10
and 20 min RT in Figure 2). Interestingly, by comparing different
samples, it can be observed that the exact composition of these
early fractions is significantly dependent on the donor. In the case
shown in Figure 3, the corresponding lines reflect the overlap of
at least three different spin systems (U1, U2, U3), as confirmed
by a TOCSY experiment carried out on a loop-collected LC-peak
at 16 min retention time.
Further characterization of these compounds would, in prin-
ciple, be possible by diffusion edited spectroscopy,26 but this was
hindered by the weak signal-to-noise ratio characterizing the
10-20 min RT region (Figure 2). The nature of U1 is not known
at this stage, but the profiles of U2 and U3 resemble sugar-like
profiles. The relatively broader profile of U2 and the singlets at
3.2 and 3.3 ppm (Figure 3) may reflect a possibly methoxylated
oligosaccharide. U3 shows clear resonances in the anomeric
region, together with an unassigned resonance at 7.4 ppm, and
MS results have identified this compound as a pentose sugar.
(31) Zambotti, F.; Blau, K.; King, G. S.; Campbell, S.; Sandler, M. Clin. Chim.
Acta 1975, 61, 247–256.
(32) Kirshon, B.; Mari, G.; Moise, K. J., Jr. Obstet. Gynecol. 1990, 75, 202–205.
(33) Kumps, A.; Vamos, E.; Mardens, Y.; Abramowicz, M.; Genin, J.; Duez, P.
J. Inherited Metab. Dis. 2004, 27, 567–579.
(34) Jauniaux, E.; Hempstock, J.; Teng, C.; Battaglia, F. C.; Burton, G. J. J. Clin.
Endocrinol. Metab. 2005, 90 (2), 1171–1175.
(35) Lentner, C.; Limited, C.-G. Geigy scientific tables; Ciba-Geigy: Basle,
Switzerland, 1981.
(36) Groenen, P. M. W.; Engelke, U. F.; Wevers, R. A.; Hendriks, J. C. M.; Eskes,
T. K. A. B.; Merkus, H. M. W. M.; Steegers-Theunissen, R. P. M. Eur. J.
Obstet. Gynecol. Reprod. Biol. 2004, 112, 16–23.
Figure 3. 1H NMR spectra taken from the LC-NMR chromatogram in Figure 2, for retention times between 12 and 18 min. (The spectra were
reprocessed with a 2 Hz line broadening and recalibrated to the ACN peak.) RG, 724; NS, 64 for all lines.































































Regarding amino acids, it is interesting to note that none of
the many amino acids, clearly identified before by NMR and
reverse-phase LC-NMR (Table 1), is observed in the ion-exchange
LC-NMR records. This is most probably due to their protonated
states, occurring at pH 2 used in this experiment, which results
in high charge densities and thus leads to the high affinity of these
compounds for the column employed here. Taurine and the newly
detected amino acid derivatives, N-acetylglycine, N-acetylalanine,
and pyroglutamate (Table 2 and Figure 4), can however be seen.
In these cases, the NH2 group is replaced by a NHR group, where
R is an acetyl or methylene group (Figure 4). This may result in
a decrease in positive charge density, at pH 2, which then would
lead to lower RTs for these compounds on the column. In the
case of taurine, the presence of a sulfonic group (Figure 4)
determines its lower retention on the anionic column used.
CONCLUSIONS
Hyphenated NMR methods have been applied to the compo-
sitional analysis of HAF, in order to rapidly identify metabolites
that could not be detected by NMR alone due to low abundance
or strong signal overlap. Reverse-phase LC conditions achieved
good separation of amino acids, some sugars, and xanthines,
among others, and coupled NMR and MS analysis enabled the
rapid identification of 30 compounds. These included 3-methyl-
2-oxovalerate and 4-aminohippurate, newly identified in HAF, to
our knowledge, and five other compounds (including some
exogenous metabolites) viewed by NMR for the first time in HAF.
Under ion-exchange LC conditions, a distinct set of over 30
compounds was detected, including sugars and organic acids, but
also several derivatives of organic acids and amino acids. Here, 5
compounds were identified in HAF for the first time (D-xylitol,
N-acetylalanine, N-acetylglycine, 2-oxoleucine, isovalerate) and a
further 10 compounds were newly seen by NMR. These results
have shown that hyphenated NMR methods enable the simulta-
neous and rapid detection of many different metabolites in HAF
and a more complete metabolite database (with 21 new assigned
compounds) to be obtained for this biofluid, compared to the
previous report based mostly on 1D and 2D NMR alone.26 This
forms the basis for metabolic studies of HAF to be carried out in
order to detect biomarkers for disorders during pregnancy.
Although quantitation of metabolites was not carried out here,
this may be possible under hyphenated conditions, using an
appropriate reference compound along with well controlled
experimental conditions.
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Figure 4. 1H NMR spectra selected from the LC-NMR chromatogram in Figure 3 and showing the elution of some amino acid derivatives: (a)
taurine, (b) N-acetylglycine, (c) pyroglutamate, and (d) N-acetylalanine. Structures and assignments are indicated. Some coeluting compounds
are identified as well as some unassigned compounds (Un). ACN, acetonitrile present in the LC system; RG, 724; NS, 64 for all lines.
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